Immune, Developmental, and Synaptic Pathways Define Bipolar Disorder Clinical Heterogeneity

Authors

Tracey van der Veen[1,2,227], Markos Tesfaye[3,4,5,6,7,227], Jessica Mei Kay Yang[8,228], Toni Boltz[9,10,11,228], Friederike S. David[12,13,228], Shane Crinion[14,228], Maria Koromina[15,16,17,228], Till F. M. Andlauer[18,19,20], Tim B. Bigdeli[3,4,21,22], Brandon J. Coombes[23], Tiffany A. Greenwood[24], Georgia Panagiotaropoulou[25], Nadine Parker[5,6], Heejong Sung[2], Nicholas Bass[1], Jonathan R. I. Coleman[26,27], José Guzman-Parra[28], Janos L. Kalman[29,30], Caroline C. McGrouther[31], Brittany L. Mitchell[32,33], Aaditya V. Rangan[31,34], Katie Scott[35], Alexey Shadrin[5,6,36], Daniel J. Smith[37], Annabel Vreeker[38,39,40], Kristina Adorjan[29,30,41], Diego Albani[42], Silvia Alemany[43,44,45], Ney Alliey-Rodriguez[46,47], Anastasia Antoniou[48], Michael Bauer[49], Eva C. Beins[12], Marco P. Boks[39], Rosa Bosch[43,50], Gerome Breen[26,27], Ben M. Brumpton[51], Nathalie Brunkhorst-Kanaan[52], Monika Budde[29], William Byerley[53], Judit Cabana-Domínguez[43,44,45], Murray J. Cairns[54,55], Bernardo Carpiniello[56], Miquel Casas[50,57,58], Pablo Cervantes[59], Chris Chatzinakos[3,4], Toni-Kim Clarke[60], Isabelle Claus[12], Cristiana Cruceanu[59,61], Alfredo Cuellar-Barboza[62,63], Piotr M. Czerski[64], Konstantinos Dafnas[48], Anders M. Dale[65], Nina Dalkner[66], J. Raymond DePaulo[67], Franziska Degenhardt[12,68], Srdjan Djurovic[7,69], Valentina Escott-Price[8], Ayman H. Fanous[70,71,72], Frederike T. Fellendorf[66], I. Nicol Ferrier[73], Liz Forty[8], Josef Frank[74], Oleksandr Frei[5,75], Nelson B. Freimer[76,77], Julie Garnham[35], Ian R. Gizer[78], Scott D. Gordon[79], Katherine Gordon-Smith[80], Tim Hahn[81], Marian L.[8], Arvid Harder[82], Martin Hautzinger[83], Urs Heilbronner[29], Dennis Hellgren[82], Stefan Herms[12,84,85], Ian B. Hickie[86], Per Hoffmann[12,84,85], Peter A. Holmans[8], Stéphane Jamain[87], Lina Jonsson[88], James L. Kennedy[89,90,91,92], Sarah Kittel-Schneider[93,94], James A. Knowles[95], Elise Koch[5,6], Manolis Kogevinas[96], Thorsten M. Kranz[52], Steven A. Kushner[97], Catharina Lavebratt[98,99], Jacob Lawrence[100], Markus Leber[101], Penelope A. Lind[32,33,102], Susanne Lucae[103], Martin Lundberg[98,99], Donald J. MacIntyre[104], Wolfgang Maier[105], Adam X. Maihofer[24,106], Dolores Malaspina[15,17], Mirko Manchia[56,107,108], Eirini Maratou[109], Lina Martinsson[110,111], Melvin G. McInnis[112], James D. McKay[113], Helena Medeiros[114], Andreas Meyer-Lindenberg[115,116], Vincent Millischer[98,99,117,118], Derek W. Morris[119], Paraskevi Moutsatsou[109], Thomas W. Mühleisen[84,120], Claire O.'Donovan[35], Catherine M. Olsen[121], Sergi Papiol[29,30,43], Antonio F. Pardiñas[8], Amy Perry[80], Andrea Pfennig[49], Claudia Pisanu[122], James B. Potash[67], Digby Quested[123,124], Mark H. Rapaport[125], Eline J. Regeer[126], John P. Rice[127], Margarita Rivera[128,129,130], Eva C. Schulte[12,29,105,131], Fanny Senner[29,30], Paul D. Shilling[24], Lisa Sindermann[12], Lea Sirignano[74], Dan Siskind[132], Claire Slaney[35], Olav B. Smeland[5,6], Janet L. Sobell[133], Maria Soler Artigas[43,44,45,134], Dan J. Stein[135], Frederike

Stein[13], Beata Swiatkowska[136], Jackson G. Thorp[32], Claudio Toma[137,138,139], Leonardo Tondo[140], Paul A. Tooney[141], Marquis P. Vawter[142], Helmut Vedder[143], James T. R. Walters[8], Stephanie H. Witt[74], Allan H. Young[144,145], Peter P. Zandi[67], Lea Zillich[74], Estonian Biobank research team[146], Genomic Psychiatry Cohort (GPC) Investigators[146], HUNT All-In Psychiatry[146], Rolf Adolfsson[147], Lars Alfredsson[148], Lena Backlund[98,99], Bernhard T. Baune[149,150,151], Frank Bellivier[152,153], Susanne Bengesser[66], Wade H. Berrettini[154], Joanna M. Biernacka[23,63], Douglas Blackwood[60], Michael Boehnke[155], Gerome Breen[27,156], Vaughan J. Carr[138], Stanley Catts[157], Sven Cichon[12,84,85,120], Aiden Corvin[158], Nicholas Craddock[8], Udo Dannlowski[81], Dimitris Dikeos[159], Tõnu Esko[160,161], Bruno Etain[152,153], Panagiotis Ferentinos[48,156], Mark Frye[63], Janice M. Fullerton[137,162], Micha Gawlik[94], Elliot S. Gershon[46,163], Fernando S. Goes[67], Melissa J. Green[137,138], Joanna Hauser[164], Frans A. Henskens[165], Jens Hjerling-Leffler[166], Ian Jones[8], Lisa A. Jones[80], René S. Kahn[15,39], John R. Kelsoe[24], Tilo Kircher[13], George Kirov[8], Nene Kobayashi[52], Mikael Landén[82,88], Marion Leboyer[87], Melanie Lenger[66], Qingqin S. Li[161,167], Jolanta Lissowska[168], Carmel Loughland[169], Jurjen J. Luykx[170,171], Nicholas G. Martin[79,172], Carol A. Mathews[173], Fermin Mayoral[28], Susan L. McElroy[174], Andrew M. McIntosh[104], Sarah E. Medland[32,175,176], Ingrid Melle[5,177], Philip B. Mitchell[138], Gunnar Morken[178,179], Richard M. Myers[180], Chiara Möser[52], Bertram Müller-Myhsok[103,181,182], Benjamin M. Neale[183,184,185], Caroline M. Nievergelt[24,106], John I. Nurnberger[186], Markus M. Nöthen[12], Michael C. O.'Donovan[8], Ketil J. Oedegaard[187,188], Tomas Olsson[189], Michael J. Owen[8], Sara A. Paciga[190], Christos Pantelis[151,191,192], Carlos N. Pato[193], Michele T. Pato[193], George P. Patrinos[194,195,196,197], Joanna M. Pawlak[164], Roy Perlis[140,198], Josep Antoni Ramos-Quiroga[43,44,45,57], Andreas Reif[52], Eva Z. Reininghaus[66], Marta Ribasés[43,44,45,134], Marcella Rietschel[74], Stephan Ripke[25,184,185], Guy A. Rouleau[199,200], Ulrich Schall[201,202], Martin Schalling[98,99], Peter R. Schofield[137,162], Thomas G. Schulze[29,67,74,203,204], Laura J. Scott[155,205], Rodney J. Scott[206,207], Alessandro Serretti[208,209], Jordan W. Smoller[184,210,211], Alessio Squassina[122], Eli A. Stahl[15,17,183], Eystein Stordal[212,213], Fabian Streit[74,115,214], Patrick F. Sullivan[82,215,216], Gustavo Turecki[217], Arne E. Vaaler[218], Eduard Vieta[219], John B. Vincent[89], Irwin D. Waldman[220], Cynthia S. Weickert[137,138,221], Thomas W. Weickert[137,138,221], David C. Whiteman[121], Martin Alda[35,222,229], Roel A. Ophoff[11,76,77,229], Kevin S. O.'Connell[5,6,229], Niamh Mullins[15,16,17,229], Andreas J. Forstner[12,120,223,229], Maria Grigoroiu-Serbanescu[224,229], Howard J. Edenberg[225,226,229], Francis J. McMahon[2,229], Ole A. Andreassen[5,6,229], Arianna Di Florio[8,216,229], Andrew McQuillin[1,229]

Affiliations

[1]Division of Psychiatry, University College London, London, UK. [2]Human Genetics Branch, Intramural Research Program, National Institute of Mental Health, NIH, US Dept of HHS, Bethesda MD USA. [3]Department of Psychiatry and Behavioral Sciences, SUNY Downstate Health Sciences University, Brooklyn, NY, USA. [4]Institute for Genomics in Health, SUNY Downstate Health Sciences University, Brooklyn, NY, USA. [5]Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway. [6]Center for Precision Psychiatry, University of Oslo, Oslo, Norway. [7]Department of Clinical Science, University of Bergen, Bergen, Norway. [8]Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK. [9]Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA. [10]Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. [11]Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. [12]Institute of Human Genetics, University of Bonn, School of Medicine and University Hospital Bonn, Bonn, Germany. [13]Department of Psychiatry and Psychotherapy, University of Marburg, Marburg, Germany. [14]Centre for Neuroimaging, Cognition and Genomics, School of Biological and Chemical Sciences and School of Psychology, University of Galway, Galway, Ireland. [15]Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA. [16]Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. [17]Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. [18]Global Computational Biology and Data Sciences, Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach an der Riß, Germany. [19]Department of Neurology, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany. [20]Max Planck Institute of Psychiatry, Munich, Germany. [21]VA NY Harbor Healthcare System, Brooklyn, NY, USA. [22]Department of Epidemiology and Biostatistics, School of Public Health, SUNY Downstate Health Sciences University, Brooklyn, NY, USA. [23]Department of Quantitative Health Sciences Research, Mayo Clinic, Rochester, MN, USA. [24]Department of Psychiatry, University of California San Diego, La Jolla, CA, USA. [25]Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin, Berlin, Germany. [26]Social, Genetic and Developmental Psychiatry Centre, King's College London, London, UK. [27]NIHR Maudsley BRC, King's College London, London, UK. [28]Mental Health Department, University Regional Hospital, Biomedicine Institute (IBIMA), Málaga, Spain. [29]Institute of Psychiatric Phenomics and Genomics (IPPG), LMU University Hospital, LMU

Munich, Munich, Germany. [30]Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany. [31]New York University, New York, NY, USA. [32]Brain and Mental Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. [33]School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia. [34]Flatiron Institute, New York, NY, USA. [35]Department of Psychiatry, Dalhousie University, Halifax, NS, Canada. [36]KG Jebsen Centre for Neurodevelopmental disorders, University of Oslo, Oslo, Norway. [37]Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK. [38]Department of Child and Adolescent Psychiatry/Psychology, Erasmus MC Sophia Children Hospital, Erasmus University, Rotterdam, The Netherlands. [39]Psychiatry, Brain Center UMC Utrecht, Utrecht, The Netherlands. [40]Department of Psychology Education and Child Studies, Erasmus School of Social and Behavioral Sciences, Erasmus University Rotterdam, The Netherlands. [41]University Hospital of Psychiatry and Psychotherapy, University of Bern, Switzerland. [42]Department of Neuroscience, Istituto Di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy. [43]Instituto de Salud Carlos III, Biomedical Network Research Centre on Mental Health (CIBERSAM), Madrid, Spain. [44]Department of Psychiatry, Hospital Universitari Vall d´Hebron, Barcelona, Spain. [45]Psychiatric Genetics Unit, Group of Psychiatry Mental Health and Addictions, Vall d´Hebron Research Institut (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain. [46]Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA. [47]Northwestern University, Chicago, IL, USA. [48]National and Kapodistrian University of Athens, 2nd Department of Psychiatry, Attikon General Hospital, Athens, Greece. [49]Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. [50]Programa SJD MIND Escoles, Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain. [51]K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway. [52]Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt am Main, Germany. [53]Psychiatry, University of California San Francisco, San Francisco, CA, USA. [54]School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, Australia. [55]Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton, NSW, Australia. [56]Section of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Italy. [57]Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. [58]Fundació Privada d'Investigació Sant Pau (FISP), Barcelona, Spain. [59]Department of Psychiatry, Mood Disorders Program, McGill University Health

Center, Montreal, QC, Canada. [60]Division of Psychiatry, University of Edinburgh, Edinburgh, UK. [61]Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. [62]Department of Psychiatry, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico. [63]Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA. [64]Department of Psychiatry, Laboratory of Psychiatric Genetics, Poznan University of Medical Sciences, Poznan, Poland. [65]Center for Multimodal Imaging and Genetics, Departments of Neurosciences, Radiology, and Psychiatry, University of California, San Diego, CA, USA. [66]Medical University of Graz, Division of Psychiatry and Psychotherapeutic Medicine, Graz, Austria. [67]Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. [68]Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany. [69]Department of Medical Genetics, Oslo University Hospital Ullevål, Oslo, Norway. [70]Department of Psychiatry, University of Arizona College of Medicine-Phoenix, Phoenix, AZ, USA. [71]Carl T. Hayden Veterans Affairs Medical Center, Phoenix, AZ, USA. [72]Banner-University Medical Center, Phoenix, AZ, USA. [73]Academic Psychiatry, Newcastle University, Newcastle upon Tyne, UK. [74]Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. [75]Institute of Clinical Medicine, University of Oslo, Oslo, Norway. [76]Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA. [77]Department of Psychiatry and Biobehavioral Science, Semel Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. [78]Department of Psychological Sciences, University of Missouri, Columbia, MO, USA. [79]Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. [80]Psychological Medicine, University of Worcester, Worcester, UK. [81]Institute for Translational Psychiatry, University of Münster, Münster, Germany. [82]Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. [83]Department of Psychology, Eberhard Karls Universität Tübingen, Tubingen, Germany. [84]Department of Biomedicine, University of Basel, Basel, Switzerland. [85]Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland. [86]Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia. [87]Univ Paris Est Créteil, INSERM, IMRB, Translational Neuropsychiatry, Créteil, France. [88]Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden. [89]Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada. [90]Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, ON, Canada. [91]Department of Psychiatry, University of Toronto, Toronto, ON, Canada. [92]Institute of Medical Sciences, University of

Toronto, Toronto, ON, Canada. [93]Department of Psychiatry and Neurobehavioral Science, University College Cork, Cork, Ireland. [94]Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital Würzburg, Würzburg, Germany. [95]Human Genetics Institute of New Jersey, Rutgers University, Piscataway, NJ, USA. [96]ISGlobal, Barcelona, Spain. [97]Department of Psychiatry, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. [98]Translational Psychiatry, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. [99]Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden. [100]Psychiatry, North East London NHS Foundation Trust, Ilford, UK. [101]Clinic for Psychiatry and Psychotherapy, University Hospital Cologne, Cologne, Germany. [102]School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia. [103]Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany. [104]Division of Psychiatry, Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK. [105]Department of Psychiatry and Psychotherapy, University of Bonn, School of Medicine and University Hospital Bonn, Bonn, Germany. [106]Research/Psychiatry, Veterans Affairs San Diego Healthcare System, San Diego, CA, USA. [107]Unit of Clinical Psychiatry, University Hospital Agency of Cagliari, Cagliari, Italy. [108]Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada. [109]National and Kapodistrian University of Athens, Medical School, Clinical Biochemistry Laboratory, Attikon General Hospital, Athens, Greece. [110]Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. [111]Centre for Psychiatry Research, SLSO Region Stockholm, Sweden. [112]Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA. [113]Genetic Cancer Susceptibility Group, International Agency for Research on Cancer, Lyon, France. [114]Institute for Genomic Health, SUNY Downstate Medical Center College of Medicine, Brooklyn, NY, USA. [115]Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. [116]German Centre for Mental Health (DZPG), Germany. [117]Department of Psychiatry and Psychotherapy, Clinical Division of General Psychiatry, Medical University of Vienna, Austria. [118]Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria. [119]Centre for Neuroimaging and Cognitive Genomics (NICOG), School of Biological and Chemical Sciences, University of Galway, Galway, Ireland. [120]Institute of Neuroscience and Medicine (INM-1), Research Centre Jülich, Jülich, Germany. [121]Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. [122]Department of Biomedical Sciences, University of Cagliari, Italy. [123]Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK. [124]Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK. [125]Department of

Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA. [126]Outpatient Clinic for Bipolar Disorder, Altrecht, Utrecht, The Netherlands. [127]Department of Psychiatry, Washington University in Saint Louis, Saint Louis, MO, USA. [128]Department of Biochemistry and Molecular Biology II, Faculty of Pharmacy, University of Granada, Granada, Spain. [129]Institute of Neurosciences ´Federico Olóriz´, Biomedical Research Center (CIBM), University of Granada, Granada, Spain. [130]Instituto de Investigación Biosanitaria ibs. GRANADA, Granada, Spain. [131]German Center for Mental Health (DZPG), partner site Munich/Augsburg, 80336, Munich, Germany. [132]Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia. [133]Psychiatry and the Behavioral Sciences, University of Southern California, Los Angeles, CA, USA. [134]Department of Genetics, Microbiology, and Statistics, Faculty of Biology, Universitat de Barcelona, Barcelona, Spain. [135]SAMRC Unit on Risk and Resilience in Mental Disorders, Dept of Psychiatry and Neuroscience Institute, University of Cape Town, Cape Town, South Africa. [136]Department of Environmental Epidemiology, Nofer Institute of Occupational Medicine, Lodz, Poland. [137]Neuroscience Research Australia, Sydney, NSW, Australia. [138]Discipline of Psychiatry and Mental Health, School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia. [139]Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid and CSIC, Madrid, Spain. [140]Department of Psychiatry, Harvard Medical School, Boston, MA, USA. [141]School of Biomedical Science and Pharmacy, University of Newcastle, Newcastle, NSW, Australia. [142]Department of Psychiatry and Human Behavior, School of Medicine, University of California, Irvine, CA, USA. [143]Psychiatry, Psychiatrisches Zentrum Nordbaden, Wiesloch, Germany. [144]Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. [145]South London and Maudsley NHS Foundation Trust, Bethlem Royal Hospital, Monks Orchard Road, Beckenham, Kent, UK. [146]A list of members and affiliations appears in the Supplement. [147]Department of Clinical Sciences, Psychiatry, Umeå University Medical Faculty, Umeå, Sweden. [148]Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. [149]Department of Psychiatry, University of Münster, Münster, Germany. [150]Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Melbourne, VIC, Australia. [151]The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia. [152]Université Paris Cité, INSERM, Optimisation Thérapeutique en Neuropsychopharmacologie, UMRS-1144, Paris, France. [153]APHP Nord, DMU Neurosciences, GHU Saint Louis-Lariboisière-Fernand Widal, Département de Psychiatrie et de Médecine Addictologique, Paris, France. [154]Psychiatry, University of Pennsylvania, Philadelphia, PA, USA. [155]Center for Statistical Genetics and Department of Biostatistics, University of

Michigan, Ann Arbor, MI, USA. [156]Social, Genetic and Developmental Psychiatry Centre, King's College London, London, UK. [157]University of Queensland, Brisbane, QLD, Australia. [158]Neuropsychiatric Genetics Research Group, Dept of Psychiatry and Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland. [159]National and Kapodistrian University of Athens, 1st Department of Psychiatry, Eginition Hospital, Athens, Greece. [160]Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia. [161]Neuroscience Therapeutic Area, Janssen Research and Development, LLC, Titusville, NJ, USA. [162]School of Biomedical Sciences, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia. [163]Department of Human Genetics, University of Chicago, Chicago, IL, USA. [164]Department of Psychiatry, Department of Psychiatric Genetics, Poznan University of Medical Sciences, Poznan, Poland. [165]School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia. [166]Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden. [167]JRD Data Science, Janssen Research and Development, LLC, Titusville, NJ, USA. [168]Cancer Epidemiology and Prevention, M. Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. [169]University of Newcastle, Newcastle, NSW, Australia. [170]Department of Psychiatry, Amsterdam University Medical Center, Amsterdam, The Netherlands. [171]Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands. [172]School of Psychology, The University of Queensland, Brisbane, QLD, Australia. [173]Department of Psychiatry and Genetics Institute, University of Florida, Gainesville, FL, USA. [174]Research Institute, Lindner Center of HOPE, Mason, OH, USA. [175]School of Psychology and Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia. [176]School of Psychology and Counselling, Queensland University of Technology, Brisbane, QLD, Australia. [177]Division of Mental Health and Addiction, University of Oslo, Institute of Clinical Medicine, Oslo, Norway. [178]Department of Mental Health, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. [179]Psychiatry, St Olavs University Hospital, Trondheim, Norway. [180]HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA. [181]Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. [182]University of Liverpool, Liverpool, UK. [183]Medical and Population Genetics, Broad Institute, Cambridge, MA, USA. [184]Stanley Center for Psychiatric Research, Broad Institute, Cambridge, MA, USA. [185]Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA. [186]Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA. [187]Division of Psychiatry, Haukeland Universitetssjukehus, Bergen, Norway. [188]Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway. [189]Department of Clinical Neuroscience and Center for Molecular Medicine,

Karolinska Institutet at Karolinska University Hospital, Solna, Sweden. [190]Human Genetics and Computational Biomedicine, Pfizer Global Research and Development, Groton, CT, USA. [191]Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne, VIC, Australia. [192]Monash Institute of Pharmaceutical Sciences (MIPS), Monash University, Parkville, VIC, Australia. [193]Rutgers Health, Rutgers University, Piscataway, New Jersey, USA. [194]University of Patras, School of Health Sciences, Department of Pharmacy, Laboratory of Pharmacogenomics and Individualized Therapy, Patras, Greece. [195]United Arab Emirates University, College of Medicine and Health Sciences, Department of Genetics and Genomics, Al-Ain, United Arab Emirates. [196]United Arab Emirates University, Zayed Center for Health Sciences, Al-Ain, United Arab Emirates. [197]Erasmus University Medical Center Rotterdam, Faculty of Medicine and Health Sciences, Department of Pathology, Clinical Bioinformatics Unit, Rotterdam, The Netherlands. [198]Center for Quantitative Health and Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. [199]Department of Neurology and Neurosurgery, McGill University, Faculty of Medicine, Montreal, QC, Canada. [200]Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada. [201]Centre for Brain and Mental Health Research, The University of Newcastle, Newcastle, NSW, Australia. [202]Hunter Medical Research Institute, New Lambton Heights, NSW, Australia. [203]Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany. [204]Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, NY, USA. [205]Pritzker Neuropsychiatric Disorders Research Consortium, University of Michigan, USA. [206]The School of Biomedical Sciences and Pharmacy, Faculty of Medicine, Health and Wellbeing, University of Newcastle, Newcastle, NSW, Australia. [207]Cancer Detection and Therapies Program, Hunter Medical Research Institute, University of Newcastle, Newcastle, NSW, Australia. [208]Department of Medicine and Surgery, Kore University of Enna, Enna, Italy. [209]Oasi Research Institute-IRCCS, Troina, Italy. [210]Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. [211]Psychiatric and Neurodevelopmental Genetics Unit (PNGU), Massachusetts General Hospital, Boston, MA, USA. [212]Department of Psychiatry, Hospital Namsos, Namsos, Norway. [213]Department of Neuroscience, Norges Teknisk Naturvitenskapelige Universitet Fakultet for naturvitenskap og teknologi, Trondheim, Norway. [214]Hector Institute for Artificial Intelligence in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. [215]Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. [216]Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. [217]Department of Psychiatry, McGill University, Montreal, QC, Canada. [218]Dept of Psychiatry, Sankt Olavs Hospital Universitetssykehuset i Trondheim, Trondheim, Norway. [219]Clinical

Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain. [220]Department of Psychology, Emory University, Atlanta, GA, USA. [21]Department of Neuroscience, SUNY Upstate Medical University, Syracuse, NY, USA. [222]National Institute of Mental Health, Klecany, Czech Republic. [223]Centre for Human Genetics, University of Marburg, Marburg, Germany. [224]Biometric Psychiatric Genetics Research Unit, Alexandru Obregia Clinical Psychiatric Hospital, Bucharest, Romania. [225]Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA. [226]Department of Medical and Molecular Genetics, Indiana University, Indianapolis, IN, USA. [227] These authors contributed as first authors: Tracey van der Veen, Markos Tesfaye. [228] These authors contributed as second authors: Jessica Mei Kay Yang, Toni Boltz, Friederike S. David, Shane Crinion, Maria Koromina. [229] These authors jointly supervised this work: Martin Alda, Roel A. Ophoff, Kevin S. O.'Connell, Niamh Mullins, Andreas J. Forstner, Maria Grigoroiu-Serbanescu, Howard J. Edenberg, Francis J. McMahon, Ole A. Andreassen, Arianna Di Florio, Andrew McQuillin.

Corresponding Author: Tracey van der Veen, University College London, Gower Street, London, WC1E 6BT, UK, (t.veen@ucl.ac.uk), +44 (0) 20 7679 2000.

Word Count (Text Only): 2994 (not including title, abstract, acknowledgement, references, tables, and figure legends).

Word Count (Abstract): 350

Number of Tables: 1

Number of Figures: 4

Key Points

Question What are the distinct genetic architectures underlying the clinical heterogeneity of bipolar disorder?

Findings In this genetic study of 23,819 bipolar disorder (BD) cases and 163,839 controls, clinical heterogeneity mapped onto four genetically-informed dimensions. A severe illness dimension was defined by a neuro-immune signature (*HLA-DMB*) shared with schizophrenia. An affective comorbidity dimension was distinguished by neurodevelopmental pathways involving axonal guidance (*DCC*). Notably, the rapid-cycling phenotype showed evidence of purifying selection, suggesting influence by rare, highly penetrant alleles.

Meaning These findings provide a data-driven biological framework for bipolar disorder, guiding future research toward patient stratification and targeted therapeutics.

Abstract

Importance The clinical heterogeneity of bipolar disorder (BD) is a major obstacle to improving diagnosis, predicting patient outcomes, and developing personalized treatments. A genetic approach is needed to deconstruct the disorder and uncover its fundamental biology. Previous genetic studies focusing on broad diagnostic categories have been limited in their ability to parse this complexity.

Objective To test the hypothesis that clinically distinct subphenotypes of BD are associated with different underlying common variant genetic architectures.

Design, Setting, and Participants This multicenter study included a primary genome-wide association study (GWAS) of up to 23,819 bipolar disorder (BD) cases and 163,839 controls. These results were integrated via multi-trait analysis of GWAS (MTAG) with external summary statistics for BD (59,287 cases; 781,022 controls) and schizophrenia (SCZ; 53,386 cases; 77,258 controls). Sample overlap was statistically accounted for.

Main Outcomes and Measures The primary outcomes were the genetic dimensions underlying BD heterogeneity, differentiated by single nucleotide polymorphism (SNP)-heritability (h^2_{SNP}), genetic correlations, genomic loci ($P \leq 5 \times 10^{-8}$), and functional, cell-type, and gene-expression pathway analyses.

Results We identified four genetically-informed dimensions of BD: Severe Illness, Core Mania, Externalizing/Impulsive Comorbidity, and Internalizing/Affective Comorbidity. The analyses yielded up to 181 subphenotype-associated loci, 53 of which are novel. The Severe Illness Dimension was characterized by a unique neuro-immune signature (a protective association with *HLA-DMB*, $P=2.50 \times 10^{-273}$) evident only when leveraging SCZ genetic data. The Internalizing/Affective dimension was associated with neurodevelopmental genes (e.g., *DCC*). Notably, the rapid-cycling subphenotype showed a unique signature of strong negative selection, a finding not observed in other subphenotypes.

Conclusions and Relevance

The clinical heterogeneity of bipolar disorder appears to be defined by a complex and multi-layered genetic architecture. The presented findings provide an empirical framework that may advance psychiatric nosology beyond its current diagnostic boundaries. These results may also inform future research to identify targets for

personalized interventions. The delineation of these genetically-informed dimensions offers specific, biologically-grounded hypotheses for subsequent therapeutic discovery. Establishing such a framework is an essential step toward refining diagnostic criteria and developing more effective, personalized treatments. This work lays the foundation for a transition from a uniform treatment model to the paradigm of precision psychiatry.

Introduction

Bipolar disorder (BD) is a severe, chronic psychiatric illness affecting around 1% of the population. The disorder has a high heritability of over 80%, and its clinical variability complicates diagnosis, treatment, and research.[1–4] Previous work established distinct genetic overlaps between BD subtypes and other major psychiatric disorders: bipolar disorder I (BD1) shows a high genetic correlation with schizophrenia (SCZ),[3,5-8] while bipolar disorder II (BD2) links more strongly to major depressive disorder (MDD) and attention-deficit/hyperactivity disorder (ADHD).[2,6,9] This overlap indicates that biological pathways are not constrained by diagnostic manuals, necessitating a data-driven approach to nosology. Given the genetic continuum between BD and SCZ, we hypothesized deconstructing severe BD requires comparing its genetic architecture with SCZ's to isolate disorder-specific from transdiagnostic risk signals. This heterogeneity impacts treatment, as features including psychosis or comorbidities guide distinct pharmacological strategies, and the iterative process of personalizing an effective regimen may contribute to the illness burden.[10]

This heterogeneity is evident across multiple clinical domains. Age of onset (AOO) is a critical factor; an earlier AOO typically signifies a greater genetic liability and a more severe disease trajectory.[11,12] An onset before 28 years of age increases the risk for psychotic features, rapid cycling (RC), comorbid anxiety disorders, alcohol or substance use disorders (AlcSUD), and suicide attempts (SA).[13] RC (defined as ≥ 4 mood episodes/year),[14] is linked to a family history of mood instability, high psychiatric comorbidity, and a lack of responsiveness to lithium, making it a challenging clinical presentation.[15,16,17] The long-observed clinical association between thyroid dysfunction and mood instability in RC is a key aspect of this profile.[18,19] While preliminary studies suggest benefits from using adjunctive thyroid hormone for RC, a definitive mechanistic link remains unproven.[17,20]

Genetic research into clinically distinct BD subphenotypes has been hampered by inadequate statistical power. This study tested the hypothesis that the clinical heterogeneity of BD is linked to underlying genetic heterogeneity defined by specific biological pathways. We employed a two-step MTAG approach, first with additional BD cases and second by integrating large-scale SCZ GWAS data, to identify specific genetic mechanisms. Our multivariate approach aimed to reveal genetic factors that confer risk for specific psychopathologies, and those that underlie the observed genetic overlaps with other major psychiatric traits.

Here, we first establish a robust genetic-clinical framework of four dimensions, and then interrogate the unique and shared biological pathways—spanning neuro-immune, neurodevelopmental, and synaptic systems—that define them.

Methods

This study used a genetic analytical pipeline (Figure 1). It received formal review and approval from appropriate institutional review boards, and written informed consent was obtained from all participants. The sample comprised 23,819 BD cases and 163,839 controls of European descent across 56 cohorts, diagnosed using international criteria.[14,21]

Standard Genome-Wide Association Study (GWAS) procedures were conducted using the RICOPILI[22] automated pipeline for quality control (QC), imputation, and association analysis. Standard QC protocols were applied. Imputation was performed against the Haplotype Reference Consortium (HRC r1.1 2016) panel,[23] with a post-imputation INFO score cutoff of 0.8. Linkage Disequilibrium Score Regression (LDSC) confirmed that confounding from population stratification was minimal (median intercept = 1.015) and was used to estimate SNP-based heritability (h^2_{SNP}).[24] QQ plots confirmed minimal inflation (eFigure 1). See Supplement for additional details.

To enhance statistical power, MTAG[25] combined our subphenotype GWAS with summary statistics from large external BD[2] and SCZ[26] GWAS (eTable 1), contingent on strong genetic correlation (rG > .70). Our two-stage MTAG design dissects genetic effects: first with external BD data for BD-centric signals, then adding SCZ data to resolve psychosis-spectrum architecture. The low median maxFDR (< .05%) confirmed a true synthesis of signals, not a distortion driven by the larger SCZ GWAS. Ten subphenotypes with reliable MTAG results were selected for downstream analysis, with Manhattan plots provided in eFigure 2.

To translate genetic associations into biological insights, FUMA v1.8.0[27] was utilized for gene-mapping and functional annotation (eTable 2), with SNP-to-gene annotations visualized in eFigure 3-4. MAGMA v1.10[28] performed gene set enrichment analysis against 17,023 curated gene sets.[29] Subphenotype cell type specificity was explored[30] using public human brain single-cell RNA-sequencing (scRNA-seq) datasets.[31-35] Conditional Transcriptome-Wide Association Studies (TWAS) using FUSION software[36] assessed the impact of genetic

variants on gene expression in 15 brain tissues, with the understanding that such associations imply but do not prove causal relationships[37]. LAVA[38] was used to identify local genetic correlations between subphenotypes. Polygenic Risk Scores (PRS) were constructed using PRS-CS-auto,[39] and their predictive power was assessed in logistic regression models, including the first ten principal components of ancestry as covariates.

Results

Identification of Four Genetic Dimensions

This study included 52% females, with a median age at interview of 22 (IQR, 17-30) years. Clinical characteristics are detailed in eTables 3-8. An assessment of phenotypic homogeneity confirmed consistent data across geographic regions (eTable 9; eFigure 5). A Confirmatory Factor Analysis (CFA) of the 11 BD subphenotypes empirically derived a robust four-factor clinical model, providing a framework for understanding BD heterogeneity (eFigure 6). This determination was supported by parallel analysis (eFigure 7). The model identified: (1) a Psychosis-Spectrum Factor (schizoaffective disorder, bipolar type [SZA], Psychosis); (2) a Core Bipolar Subtype Factor (BD1, BD2); (3) a Comorbidity and Mood Instability Factor (RC, panic disorder [PD], obsessive compulsive disorder [OCD], AlcSUD, SA, unipolar mania [UM][40-42]); and (4) an Age of Onset Factor. Full details of the factor loadings and model fit are available in S1. An *a priori* (eFigure 8) and subsequent Principal Component Analysis (PCA) of MTAG loci aligned with these clinical factors (eFigure 9), underscoring a genetic basis for the observed clinical distinctions. This genetic PCA explained 81.5% of the variance and revealed four distinct dimensions, or clusters, that may represent points along a biological continuum rather than discrete entities. The statistical validity of this structure was confirmed by a one-way ANOVA, which revealed a robust difference in local genetic correlation (ρ) between the clusters, $F(3, 1038) = 203.2$, $P < 2.00 \times 10^{-16}$.

The four dimensions were interpreted as representing:

- A **Severe Illness** Dimension (Psychosis, SZA)
- A **Core Mania** Dimension (BD1)
- An **Externalizing/Impulsive Comorbidity** Dimension (SA, AlcSUD)
- An **Internalizing/Affective Comorbidity** Dimension (BD2, PD, OCD, RC, UM)

Dimension 1: Severe Illness

This dimension is defined by profound genetic overlap with SCZ, a link substantiated by our analyses (eFigure 10) and consistent with large-scale genomic dissections of the two disorders.[43],[44] The inclusion of SCZ variants in our MTAG massively amplified shared signals; for instance, the number of shared loci between Psychosis and SZA increased by 63% (from 16 to 26) in the BD-SCZ analysis (eTable 10). Biologically, this dimension is differentiated by a unique neuro-immune signature. The TWAS analysis revealed that expression of *HLA-DMB* in the cerebellum showed a strong protective association ($P = 2.50 \times 10^{-273}$) only in the BD-SCZ MTAG context; this signal was not robust in the BD-only analysis, indicating this specific immune pathway is a primary feature linking severe BD to SCZ (eTable 11; Figure 2, eFigure 11). This synaptic link is mirrored at the cellular level, where the genetic enrichment for GABAergic and cortical neurons became more robust in the BD-SCZ context (P-adjusted for Psychosis-BD GABAergic neurons $= 3.39 \times 10.0^{-7}$ vs. 1.96×10^{-11} for Psychosis-BD-SCZ), underscoring a shared cellular vulnerability (eTable 12; Figure 3, eFigure 12). Furthermore, this dimension is characterized by specific synaptic biology. The novel, deleterious variant in the neuronal sodium channel gene *SCN2A* (Combined Annotation Dependent Depletion[CADD]=19.83)[45] was associated specifically with the Psychosis and BD1 subphenotypes (eTable 13), directly implicating fundamental neuronal excitability. This is mirrored in the gene-set analysis, where the significance for pathways including "GOCC_POSTSYNAPTIC_SPECIALIZATION", driven by genes involved in scaffolding proteins and glutamatergic receptor subunits, became orders of magnitude stronger for this cluster when SCZ data was added (e.g., for SZA, P (Bonferroni) $= 1.35 \times 10^{-12}$), confirming that the shared biology is concentrated at the synapse (eTable 14; Figure 4, eFigure 13).

Dimension 2: Core Mania

While genetically related to the Severe Illness Dimension, the BD1 dimension is distinguished by specific loci related to neuronal function and development. The TWAS analysis identified *PACS1*, involved in neuronal protein trafficking, as uniquely associated with BD1 via its expression in the cortex (eTable 15). The association with *PACS1* suggests altered neurotrophic support may be a specific biological feature of the core manic phenotype. Furthermore, BD1 was specifically associated with a variant in *ADCY2* (rs78308718), a gene previously linked to lithium response.[46-49] This suggests a distinct biological pathway related to treatment response that is characteristic of this core manic phenotype. This was complemented by findings for *CACNA1C*, a well-established risk gene for BD, which showed its strongest association within the Core Mania dimension,

reinforcing the importance of calcium channel signaling in mania.[3] This contrast is particularly evident when comparing BD1 and RC; while BD1 shows genetic specificity, RC displays a highly pleiotropic profile, with associated variants overlapping extensively with other subphenotypes (eFigure 14).

Dimension 3: Externalizing/Impulsive

This dimension is defined by a strong shared liability for impulsive and externalizing behaviors. This was evident in the high global genetic correlation between suicide attempt (SA) and alcohol/substance use disorder (AlcSUD) (rG ≈ .80, s.e.m.=.056, eFigure 10) and was validated by LAVA, which identified three shared local genetic loci between them (eTable 16). The three local genetic loci shared between SA and AlcSUD included a region on chromosome 16 containing genes for synaptic vesicle transport, suggesting shared mechanisms of presynaptic function. Genetically, this dimension shares a common architecture with ADHD (eTable 17). Biologically, this dimension is distinguished by a strong enrichment for midbrain dopaminergic neurons, directly implicating reward and motivation pathways in the shared genetic risk for both SA and AlcSUD (eTable 12). The enrichment for dopaminergic neurons was specific to cells from the ventral tegmental area (VTA), a key hub in the mesolimbic reward circuit, providing a direct anatomical and cellular correlate for the high rates of comorbid substance use in this cluster. The novel association of the gene *MAD1L1*, critical for neurodevelopment, with the AlcSUD subphenotype in the BD-SCZ MTAG provides a specific biological link for this dimension (Table 1).

Dimension 4: Internalizing/Affective

This broad dimension is underpinned by a complex web of shared genetic factors related to mood instability and anxiety. While sharing the core cellular vulnerabilities seen across all clusters (e.g., GABAergic neurons, astrocytes), its distinction comes from specific gene pathways. The most powerful evidence for this clustering comes from our LAVA analysis, which uncovered a hidden relationship between OCD and PD. Despite a moderate global correlation, these two subphenotypes shared 30 local genetic loci, explaining their clustering and demonstrating a specific, shared genetic architecture for anxiety-compulsive traits that is largely independent of the psychosis axis (eTable 16; eFigure 15). The 30 shared loci between OCD and PD were significantly enriched for genes involved in postsynaptic density scaffolding and calcium signaling, suggesting a shared vulnerability based on the molecular machinery of the synapse in corticostriatal circuits. Biologically, this dimension is linked by specific neurodevelopmental and signaling pathways. A novel association of the

neurodevelopmental guidance gene *DCC* was shared across the RC, UM, PD, and OCD sub-group, suggesting altered axonal guidance as a shared vulnerability pathway (Table 1). A more specific link between rapid cycling (RC) and PD was the shared association with *SMAD3*, a gene that mediates C4-regulating TGF-β signaling, a pathway known to interact with thyroid hormones,[50] and genes such as *SMAD*[51] and *DGKH*[52],[53] have been previously linked to panic disorder. This provides a potential biological mechanism for the long-observed, but mechanistically elusive, association between thyroid dysfunction and mood instability in RC. Finally, SBayesS analysis further differentiated this cluster by showing that BD2's genetic architecture overlaps most strongly with anxiety disorders, in contrast to BD1's primary overlap with SCZ (eTable 17; Figure 16), providing a clear genetic basis for their separation. The clinical presentation of this dimension is further explored by examining the relationship between AOO and comorbidity count (eFigure 17).

Overall Genetic Discovery and Prediction

The foundational genome-wide summary statistics for the analyzed subphenotypes are available (eTable 18)(103 loci identified, mainly BD1). MTAG enhanced discovery, identifying up to 181 subphenotype-associated loci (eTable 19), including 53 novel loci not previously linked to the subphenotype, BD, or SCZ (Table 1; eTable 13). Overlap of these loci is visualized in eFigure 18 and eFigure 19. Replication of previously identified loci was confirmed (eTable 20). PRS demonstrated effective predictive power, with variance explained on the liability scale (R2-liability) ranging from 5.47% for PD to 12.40% for unipolar mania (eTables 21-22); see eTable 23 for prevalences. SNP-based heritability (eTable 24) was highest for the psychosis subphenotype at .278 (s.e.m.=.017). Genetic correlations between our univariate GWAS and final MTAG results are shown in eTable 25. Additional analyses confirmed methodological consistency (eFigure 20). The statistical validity of this transdiagnostic approach was confirmed by enrichment of our primary credible gene set (eTables 26-29) for established rare-variant risk genes from the SCHEMA consortium (eTable 30; $P = 4.10 \times 10^{-4}$), indicating that the identified loci represent biological convergence rather than statistical artifact.

Discussion

Our investigation reveals that the clinical heterogeneity of BD is rooted in a multi-layered interplay of shared and subphenotype-specific genetic factors. We confirmed a core architecture affecting fundamental cellular processes, while identifying distinct genetic signatures that align with clinical subphenotypes. This evidence supports a dimensional approach to nosology, challenging a purely categorical view.[54],[43] While these dimensions may not reflect distinct etiologies, they likely represent a continuum of genetic liability where different clinical features emerge at varying thresholds of risk. However, an alternative interpretation must be considered: that these dimensions do not reflect truly distinct etiologies, but rather a single continuum of genetic liability where different clinical features, such as psychosis or comorbidity, emerge at varying thresholds of risk. This dimensional framework represents a step toward precision psychiatry, offering a new lens through which to view patients not as holders of a single diagnosis, but as individuals situated along multiple, biologically-defined continua of risk. The fact that anxiety-related subphenotypes share core synaptic enrichments with severe psychotic subphenotypes suggests a unified biological basis that can manifest in diverse ways, supported by our local correlation analyses.

Notable gene findings provide leads for understanding pathophysiology. The deleterious *SCN2A* variant as a strong BD1 marker suggests a role for ion channel dysfunction,[2-3],[5],[26],[55] potentially disrupting activity in brain regions critical for mood regulation and plasticity, such as the hippocampus where adult neurogenesis occurs.[56] The pleiotropic *SLC39A8* variant, a known SCZ risk factor, was novel for seven subphenotypes and points to shared mechanisms involving metal homeostasis and mitochondrial function.[57-59] The novel association of the neurodevelopmental guidance gene *DCC* with the RC, UM, PD, and OCD cluster suggests a shared mechanism of altered axon guidance during brain formation.[49] The finding that altered axonal guidance underpins a cluster of internalizing and mood instability disorders is particularly compelling. Other notable findings include *FOXO6* (FOX genes implicated in personality disorders)[60-61] associated with most subphenotypes but not BD1, and *PBRM1*[62],[2],[5],[63] (linked to mood-incongruent psychosis) replicated in BD1.[2] Our findings add to a complex genetic landscape for bipolar disorder that includes previously established risk loci such as 3p21.1,[63] and pathways involving endocannabinoid signaling[64],[65] and genes including *CHDH*.[66]

Biological annotations showed broadly similar enrichments in synapse biology. Notably, BD2 displayed weaker genetic association with glutamatergic pyramidal cells versus GABAergic interneurons, consistent with

depression[67] and contrasting with SCZ's increased glutamatergic signaling.[68] Such cellular pathway distinctions could underpin differential treatment responses. For example, *PACS1* (unique to BD1) links to excitatory/inhibitory imbalance.[2],[3],[5] the massive amplification of the protective *HLA-DMB* signal when considering SCZ variants supports an integrated neuro-immune hypothesis where foundational neuronal vulnerabilities are compounded by aberrant immune responses. The specificity of this signal suggests the immune component of risk is most relevant at the severe, psychotic end of the mood disorder spectrum, potentially providing a biomarker to stratify patients for immunomodulatory trials. This connects to other immune-related genes, such as *ZSCAN9* and *C4A*, linked to brain structure and synaptic pruning.[69],[70] While broad analyses suggest *C4* may not be central to BD overall[5],[55], there is emerging evidence for its importance at the subphenotype level, particularly in psychosis.[71]

Our genetic analyses illuminate distinct biological underpinnings for clinical subtypes. BD1 demonstrates a strong genetic overlap with schizophrenia, characterized by the deleterious *SCN2A* variant. In contrast, UM clustered within the Comorbidity and Mood Instability Factor, suggesting that while UM manifests as mania, its genetic liability draws more heavily from a general predisposition to comorbidity rather than from the core psychosis-spectrum vulnerability. This implies the manic syndrome can be an endpoint for multiple distinct biological pathways. The distinct genetic signature of UM validates its unique position in psychiatric nosology and suggests it should be considered a separate entity in clinical trial design.

A novel finding was that RC exhibited a unique genetic signature characterized by the most pronounced negative selection signatures.[72] the clinical profile of RC—early-onset, highly comorbid, and treatment-refractory—provides a rationale for this novel observation. This evidence suggests the genetic architecture of RC may be disproportionately influenced by rarer, more highly penetrant risk alleles that are actively purged from the population due to their severe fitness consequences. While compelling, this signature could also be confounded by the severe functional impairment and social instability of the phenotype, which independently impact reproductive fitness. This aligns with the clinical severity and early onset of the phenotype, providing a compelling rationale for dedicated studies of rare and de novo variation in well-phenotyped RC cohorts. This sets RC apart from other BD presentations and indicates that future research should expand beyond common variant GWAS to fully capture its etiology. The shared genetic link to *SMAD3* in RC and PD offers the first potential mechanistic bridge for the long-observed clinical association between thyroid dysfunction and mood instability in RC, via the gene's role in thyroid-interacting TGF-β signaling.[18]

Limitations and Future Research

Our study's primary reliance on cohorts of European ancestry limits generalizability, underscoring the need for future multi-ancestry validation. While MTAG[25] enhances power, its focus on intersected variants may mask unique loci. Despite rigorous QC, cohort heterogeneity and diagnostic biases remain considerations. For instance, observed genetic distinctions could be inflated by diagnostic practices (e.g., assigning comorbidities based on a primary diagnosis of SZA vs BD with psychosis). Future research must translate these associations into precise mechanistic understandings via functional genomics. Validation in larger, independent, multi-ancestry meta-analyses is crucial. Finally, conducting de novo GWAS on the four clinical factors identified here will provide deeper insights, potentially enabling biologically informed diagnostic systems and novel, personalized therapeutics.

Conclusion

Pervasive neurodevelopmental factors, coupled with a robust neuro-immune component and core deficits in synaptic function, clarify BD's etiology. Our study offers a multi-layered understanding of BD's genetic heterogeneity. These findings move BD research towards a more biologically grounded psychiatric nosology, which is a foundational step toward enabling better patient stratification and paving the way for targeted therapeutic strategies that address specific vulnerabilities in this complex illness.

Article Information

Corresponding Author: Tracey van der Veen, University College London, Gower Street, London, WC1E 6BT, UK, (t.veen@ucl.ac.uk), +44 (0) 20 7679 2000.

Author Contributions: The management group, comprising a subset of authors, was responsible for the study design, conduct, primary and final interpretation, and included M.A., R.A.O., K.S.O., N.M., A.J.F., M.G-S., H.J.E., F.J.M.,O.A.A., A.D.F., and A.M. The writing group for the paper was led by A.D.F. and A.M; this group was also responsible for primary drafting and editing of the manuscript. M.T. contributed clinical assessments and analyses of the clinical data. T.V. was responsible for the main analyses presented in the paper and included modified analytical code provided by J.M.K.Y., T.B., F.S.D., and K.S.O. Numerous authors beyond the initial writing group contributed to data interpretation and provided edits, comments and suggestions to the paper. All authors reviewed the manuscript critically for important intellectual content and approved the final version of the manuscript for publication. The Chair of the PGC is P.F.S. The Bipolar Disorder Working Group of the PGC is led by O.A.A.

Conflict of Interest Disclosures: E.A.S. is an employee of Regeneron Genetics Center and owns stocks of Regeneron Pharmaceutical Co. Multiple additional authors work for pharmaceutical or biotechnology companies in a manner directly analogous to academic coauthors and collaborators. A.H.Y. has given paid lectures and served on advisory boards relating to drugs used in affective and related disorders for several companies (AstraZeneca, Eli Lilly, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allergan, Bionomics and Sumitomo Dainippon Pharma), was Lead Investigator for Embolden Study (AstraZeneca), BCI Neuroplasticity study and Aripiprazole Mania Study, and is an investigator for Janssen, Lundbeck, Livanova and Compass. J.I.N. is an investigator for Janssen. P.F.S. reports the following potentially competing financial interests: Neumora Therapeutics (advisory committee and shareholder). G. Breen reports consultancy and speaker fees from Eli Lilly and Illumina and grants funding from Eli Lilly. M. Landen has received speaker fees from Lundbeck. O.A.A. has served as a speaker for Janssen, Lundbeck, and Sunovion and as a consultant for Cortechs.ai. A.M.D. is a founder of and holds equity interest in CorTechs Labs and serves on its scientific advisory board; he is a member of the scientific advisory board of Human Longevity and the Mohn Medical Imaging and Visualization Center (Bergen, Norway); and he has received research funding from General

Electric Healthcare. E.V. has received grants and served as a consultant, advisor or CME speaker for the following entities: AB Biotics, Abbott, Allergan, Angelini, AstraZeneca, Bristol Myers Squibb, Dainippon Sumitomo Pharma, Farmindustria, Ferrer, Forest Research Institute, Gedeon Richter, GlaxoSmithKline, Janssen, Lundbeck, Otsuka, Pfizer, Roche, SAGE, Sanofi Aventis, Servier, Shire, Sunovion, Takeda, the Brain and Behaviour Foundation, the Catalan Government (AGAUR and PERIS), the Spanish Ministry of Science, Innovation, and Universities (AES and CIBERSAM), the Seventh European Framework Programme and Horizon 2020 and the Stanley Medical Research Institute. S.K.S. received authors, speakers and consultant honoraria from Janssen, Medice Arzneimittel Putter GmbH and Takeda outside of the current work. A.S. is or has been a consultant/speaker for: Abbott, Abbvie, Angelini, AstraZeneca, Clinical Data, Boheringer, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Innovapharma, Italfarmaco, Janssen, Lundbeck, Naurex, Pfizer, Polifarma, Sanofi, Servier. J.R.D. has served as an unpaid consultant to Myriad Neuroscience (formerly Assurex Health) in 2017 and 2019 and owns stock in CVS Health. B.M.N. is a member of the scientific advisory board at Deep Genomics and consultant for Camp4 Therapeutics, Takeda Pharmaceutical and Biogen. I.B.H. is the Co-Director of Health and Policy at the Brain and Mind Centre (BMC) University of Sydney. The BMC operates an early-intervention youth services at Camperdown under contract to Headspace. He is the Chief Scientific Advisor to, and a 3.2% equity shareholder in, InnoWell Pty Ltd. InnoWell was formed by the University of Sydney (45% equity) and PwC (Australia; 45% equity) to deliver the $30 M Australian Government funded Project Synergy (2017to 2020; a three year program for the transformation of mental health services) and to lead transformation of mental health services internationally through the use of innovative technologies. M.J.O. and M.C.O.D. have received funding from Takeda Pharmaceuticals and Akrivia Health outside the scope of the current work. P.B.M. has received remuneration from Janssen (Australia) and Sanofi (Hangzhou) for lectures or advisory board membership. T.E.T., H.S. and K.S. are employed by deCODE Genetics/Amgen. J.A.R-Q. was on the speakers' bureau and/or acted as consultant for Biogen, Idorsia, Casen-Recordati, Janssen-Cilag, Novartis, Takeda, Bial, Sincrolab, Neuraxpharm, Novartis, BMS, Medice, Rubió, Uriach, Technofarma and Raffo in the past 3 years; has also received travel awards (airplane tickets and hotel) for taking part in psychiatric meetings from Idorsia, Janssen-Cilag, Rubió, Takeda, Bial and Medice; and the Department of Psychiatry chaired by J.A.R-Q. received unrestricted educational and research support from the following companies in the past 3 years: Exeltis, Idorsia, Janssen-Cilag, Neuraxpharm, Oryzon, Roche, Probitas and Rubió. All other authors declare no financial interests or potential conflicts of interest.

Funding/Support: The PGC has received major funding from the US National Institute of Mental Health (PGC4: R01 MH124839, PGC3: U01 MH109528, PGC2: U01 MH094421 and PGC1: U01 MH085520). Individual and cohort-specific funding acknowledgements are detailed in the Supplement. T.V. is supported in part by the National Institutes of Health (NIH) Graduate Partnership Program (GPP).

Role of the Funder/Sponsor: The content is solely the responsibility of the authors and does not necessarily represent the official views of the US National Institutes of Health.

Data Sharing Statement: The genome-wide association summary statistics for all analyses presented here will be made publicly available via the Psychiatric Genomics Consortium (https://www.med.unc.edu/pgc/download-results/) upon publication of this article. Genotype data are available for a subset of cohorts, including dbGAP accession numbers and/or restrictions, as described in the Supplement.

Additional Contributions (Acknowledgments): Permission was obtained for statistical analyses to be carried out on the NL Genetic Cluster Computer (http://www.geneticcluster.org) hosted by SURFsara.

Code Availability: No custom code was developed for this study. Figures 2 and 3 were generated using publicly available code originally developed by Tabea Schoeler (GitHub: https://github.com/TabeaSchoeler). All software and tools used for the analyses presented are publicly available and referenced within the respective sections in the Methods of the article or supplement.

AI Use Disclosure: No AI tools were used in the preparation of this manuscript.

References

1. Oliva V, Fico G, De Prisco M, Gonda X, Rosa AR, Vieta E. Bipolar disorders: an update on critical aspects. *Lancet Reg Health Eur*. 2024;48:101135. Published 2024 Nov 29. doi:10.1016/j.lanepe.2024.101135.

2. O'Connell KS, Koromina M, van der Veen T, et al. Genomics yields biological and phenotypic insights into bipolar disorder. Nature. 2025;639(8056):968-975.

3. Stahl EA, Breen G, Forstner AJ, et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat Genet. 2019;51(5):793-803.

4. McGuffin P, Rijsdijk F, Andrew M, Sham P, Katz R, Cardno A. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry. 2003;60(5):497-502. doi:10.1001/archpsyc.60.5.497.

5. Mullins N, Forstner AJ, O'Connell KS, et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nat Genet. 2021;53(6):817-829.

6. Lawrence JM, Breunig S, Foote IF, Tallis CB, Grotzinger AD. Genomic SEM applied to explore etiological divergences in bipolar subtypes. Psychol Med. 2024;54(6):1152-1159.

7. Bipolar Disorder and Schizophrenia Working Group of the Psychiatric Genomics Consortium. Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes. Cell. 2018;173(7):1705-1715.e16.

8. Richards AL, Cardno A, Harold G, et al. Genetic Liabilities Differentiating Bipolar Disorder, Schizophrenia, and Major Depressive Disorder, and Phenotypic Heterogeneity in Bipolar Disorder. JAMA Psychiatry. 2022;79(10):1032-1039.

9. Grigoroiu-Serbanescu M, Giaroli G, Thygesen JH, et al. Predictive power of the ADHD GWAS 2019 polygenic risk scores in independent samples of bipolar patients with childhood ADHD. J Affect Disord. 2020;265:651-659.

10. Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013;381(9878):1672-1682. doi:10.1016/S0140-6736(13)60857-0.

11. Kalman JL, Olde Loohuis LM, Vreeker A, et al. Characterisation of age and polarity at onset in bipolar disorder. Br J Psychiatry. 2021;219(6):659-669.

12. Lefrere A, Godin O, Jamain S, et al. Refining Criteria for a Neurodevelopmental Subphenotype of Bipolar Disorders. Biol Psychiatry. 2025;97(8):806-815.

13. Lin PI, McInnis MG, Potash JB, et al. Clinical correlates and familial aggregation of age at onset in bipolar disorder. Am J Psychiatry. 2006;163(2):240-246.

14. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 4th ed. American Psychiatric Association; 1994.

15. Saunders EH, Scott LJ, McInnis MG, Burmeister M. Familiality and diagnostic patterns of subphenotypes in the National Institutes of Mental Health bipolar sample. Am J Med Genet B Neuropsychiatr Genet. 2008;147B(1):18-26.

16. Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry. 1974;30(2):229-233.

17. Miola A, Fountoulakis KN, Baldessarini RJ, et al. Prevalence and outcomes of rapid cycling bipolar disorder: Mixed method systematic meta-review. J Psychiatr Res. 2023;164:404-415.

18. Bauer M, Whybrow PC. Thyroid hormone, neural tissue and mood modulation. World J Biol Psychiatry. 2001;2(2):59-69. doi:10.3109/15622970109027495.

19. Bauer M, Goetz T, Glenn T, Whybrow PC. The thyroid-brain interaction in thyroid disorders and mood disorders. J Neuroendocrinol. 2008;20(10):1101-1114.

20. Walshaw PD, Gyulai L, Bauer M, et al. Adjunctive thyroid hormone treatment in rapid cycling bipolar disorder: A double-blind placebo-controlled trial of levothyroxine (L-T4) and triiodothyronine (T3). Bipolar Disord. 2018;20(7):594-603.

21. World Health Organization. *International Statistical Classification of Diseases and Related Health Problems*. 10th ed. World Health Organization; 2010.

22. Lam M, Awasthi S, Watson HJ, et al. RICOPILI: Rapid Imputation for COnsortias PIpeLIne. Bioinformatics. 2020;36(3):930-933.

23. McCarthy S, Das S, Kretzschmar W, et al. A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet*. 2016;48(10):1279-1283. doi:10.1038/ng.3643.

24. Bulik-Sullivan BK, Loh PR, Finucane HK, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet. 2015;47(3):291-295.

25. Turley P, Walters RK, Maghzian O, et al. Multi-trait analysis of genome-wide association summary statistics using MTAG. Nat Genet. 2018;50(2):229-237.

26. Trubetskoy V, Pardiñas AF, Qi T, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. 2022;604(7906):502-508.

27. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. Nat Commun. 2017;8(1):1826.

28. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol. 2015;11(4):e1004219.

29. Liberzon A, Subramanian A, Pinchback R, et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739-1740.

30. Watanabe K, Umićević Mirkov M, de Leeuw CA, et al. Genetic mapping of cell type specificity for complex traits. Nat Commun. 2019;10(1):3222.

31. Wang D, Liu S, Warrell J, et al. Comprehensive functional genomic resource and integrative model for the human brain. Science. 2018;362(6420):eaat8464.

32. Hodge RD, Bakken TE, Miller JA, et al. Conserved cell types with divergent features in human versus mouse cortex. Nature. 2019;573(7772):61-68.

33. Habib N, Avraham-Davidi I, Basu A, et al. Massively parallel single-nucleus RNA-seq with DroNc-seq. Nat Methods. 2017;14(10):955-958.

34. La Manno G, Gyllborg D, Codeluppi S, et al. Molecular Diversity of Midbrain Development in Mouse, Human, and Stem Cells. Cell. 2016;167(2):566-580.e19.

35. Hochgerner H, Lönnerberg P, Hodge R, et al. STRT-seq-2i: dual-index 5' single cell and nucleus RNA-seq on an addressable microwell array. Sci Rep. 2017;7(1):16327.

36. Gusev A, Ko A, Shi H, et al. Integrative approaches for large-scale transcriptome-wide association studies. Nat Genet. 2016;48(3):245-252.

37. de Leeuw C, Werme J, Savage JE, Peyrot WJ, Posthuma D. On the interpretation of transcriptome-wide association studies. PLoS Genet. 2023;19(9):e1010921.

38. Werme J, van der Sluis S, Posthuma D, de Leeuw CA. An integrated framework for local genetic correlation analysis. Nat Genet. 2022;54(3):274-282.

39. Ge T, Chen CY, Ni Y, Feng YA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. Nat Commun. 2019;10(1):1776.

40. Nurnberger J Jr, Roose SP, Dunner DL, Fieve RR. Unipolar mania: a distinct clinical entity?. Am J Psychiatry. 1979;136(11):1420-1423.

41. Mehta S. Unipolar mania: recent updates and review of the literature. Psychiatry J. 2014;2014:261943.

42. Manchia M, Miola A, Tondo L, Baldessarini RJ. Unipolar Mania: Prevalence and Patient Characteristics. Acta Psychiatr Scand. Published online March 9, 2025.

43. Mallard TT, Linnér RK, Grotzinger AD, et al. Multivariate GWAS of psychiatric disorders and their cardinal symptoms reveal two dimensions of cross-cutting genetic liabilities. Cell Genom. 2022;2(6):100140.

44. Grotzinger AD, Werme J, Peyrot WJ, et al. The landscape of shared and divergent genetic influences across 14 psychiatric disorders. *medRxiv*. Posted online January 14, 2025. doi:10.1101/2025.01.14.25320574.

45. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46(3):310-315.

46. Song J, Bergen SE, Di Florio A, et al. Genome-wide association study identifies SESTD1 as a novel risk gene for lithium-responsive bipolar disorder [published correction appears in Mol Psychiatry. 2017 Aug;22(8):1223. doi: 10.1038/mp.2016.246.]. Mol Psychiatry. 2016;21(9):1290-1297.

47. International Consortium on Lithium Genetics (ConLi+Gen), Amare AT, Schubert KO, et al. Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder: A Genome-Wide Association Study. JAMA Psychiatry. 2018;75(1):65-74.

48. McQuillin A, Yao K, Nadeem A, et al. Implication of the ADCY1 Gene in Lithium Response in Bipolar Disorder by Genome-wide Association Meta-analysis. Preprint. Research Square. Posted online January 8, 2024.

49. Osete JR, Akkouh IA, Ievglevskyi O, et al. Transcriptional and functional effects of lithium in bipolar disorder iPSC-derived cortical spheroids. Mol Psychiatry. 2023;28(7):3033-3043.

50. Alonso-Merino E, Martín Orozco R, Ruíz-Llorente L, et al. Thyroid hormones inhibit TGF-β signaling and attenuate fibrotic responses. Proc Natl Acad Sci U S A. 2016;113(24):E3451-E3460.

51. Forstner AJ, Awasthi S, Wolf C, et al. Genome-wide association study of panic disorder reveals genetic overlap with neuroticism and depression. Mol Psychiatry. 2021;26(8):4179-4190.

52. Gregersen NO, Lescai F, Liang J, et al. Whole-exome sequencing implicates DGKH as a risk gene for panic disorder in the Faroese population. Am J Med Genet B Neuropsychiatr Genet. 2016;171(8):1013-1022.

53. Baum AE, Akula N, Cabanero M, et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry. 2008;13(2):197-207.

54. Grotzinger AD, Mallard TT, Akingbuwa WA, et al. Genetic architecture of 11 major psychiatric disorders at biobehavioral, functional genomic and molecular genetic levels of analysis. Nat Genet. 2022;54(5):548-559.

55. Koromina M, Ravi A, Panagiotaropoulou G, et al. Fine-mapping genomic loci refines bipolar disorder risk genes. Preprint. medRxiv. 2024;2024.02.12.24302716.

56. Eriksson PS, Perfilieva E, Björk-Eriksson T, et al. Neurogenesis in the adult human hippocampus. Nat Med. 1998;4(11):1313-1317.

57. Nebert DW, Liu Z. SLC39A8 gene encoding a metal ion transporter: discovery and bench to bedside. Hum Genomics. 2019;13(Suppl 1):51.

58. Mealer RG, Jenkins BG, Chen CY, et al. The schizophrenia risk locus in SLC39A8 alters brain metal transport and plasma glycosylation. Sci Rep. 2020;10(1):13162.

59. Mealer RG, Williams SE, Noel M, et al. The schizophrenia-associated variant in SLC39A8 alters protein glycosylation in the mouse brain. Mol Psychiatry. 2022;27(3):1405-1415.

60. Witt SH, Streit F, Jungkunz M, et al. Genome-wide association study of borderline personality disorder reveals genetic overlap with bipolar disorder, major depression and schizophrenia. Transl Psychiatry. 2017;7(6):e1155.

61. Streit F, Awasthi S, Hall ASM, et al. Genome-wide association study of borderline personality disorder identifies six loci and highlights shared risk with mental and somatic disorders. medRxiv. Published online November 12, 2024.

62. Goes FS, Hamshere ML, Seifuddin F, et al. Genome-wide association of mood-incongruent psychotic bipolar disorder. Transl Psychiatry. 2012;2(10):e180.

63. McMahon FJ, Akula N, Schulze TG, et al. Meta-analysis of genome-wide association data identifies a risk locus for major mood disorders on 3p21.1. Nat Genet. 2010;42(2):128-131.

64. Wilson RI, & Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 2001;410(6828):588-592.

65. Tao R, Li C, Jaffe AE, et al. Cannabinoid receptor CNR1 expression and DNA methylation in human prefrontal cortex, hippocampus and caudate in brain development and schizophrenia. Transl Psychiatry. 2020;10(1):158.

66. Chang H, Li L, Peng T, et al. Identification of a Bipolar Disorder Vulnerable Gene CHDH at 3p21.1. Mol Neurobiol. 2017;54(7):5166-5176.

67. Lüscher B, Shen Q, Sahir N. The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry. 2011;16(4):383-406.

68. Poels EM, Kegeles LS, Kantrowitz JT, et al. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry. 2014;19(1):20-29.

69. O'Connell KS, Sønderby IE, Frei O, et al. Association between complement component 4A expression, cognitive performance and brain imaging measures in UK Biobank. Psychol Med. Published online March 3, 2021.

70. Borbye-Lorenzen N, Zhu Z, Agerbo E, et al. The correlates of neonatal complement component 3 and 4 protein concentrations with a focus on psychiatric and autoimmune disorders. Cell Genom. 2023;3(12):100457.

71. Hörbeck E, Jonsson L, Malwade S, Karlsson R, Pålsson E, Sigström R, et al. Dissecting the impact of complement component 4A in bipolar disorder. Brain, Behavior, and Immunity. 2024;116:150-9.

72. Zeng J, Xue A, Jiang L, et al. Widespread signatures of natural selection across human complex traits and functional genomic categories. Nat Commun. 2021;12(1):1164.

Figure 1. Overview of the Study Design and Analytical Workflow. This diagram illustrates the multi-stage analytical pipeline, beginning with cohort collection and proceeding through genome-wide association studies (GWAS), statistical enhancement with Multi-Trait Analysis of GWAS (MTAG), and concluding with downstream biological interpretation to identify key pathways and mechanisms.

Figure 2. Top Gene Expression Associations from the bipolar disorder-schizophrenia (BD-SCZ) Transcriptome-Wide Association Study (TWAS). The plot shows the most significant, conditionally independent gene-tissue associations for each BD subphenotype. The x-axis represents the significance of the association (-log₁₀ P-value), corrected for all genes and tissues tested. The direction of effect is indicated by triangles: red for a positive Z-score (increased expression associated with risk) and blue for a negative Z-score (decreased expression associated with risk). Corresponding results from the BD-only analysis are shown in eFigure 11. The eTable 15 provides the full list of gene-tissue associations from the TWAS analysis.

Figure 3. Cell-Type Enrichment Results from the bipolar disorder-schizophrenia (BD-SCZ) Analysis. The heatmap displays standardized beta coefficients from cell-type enrichment analysis across 10 BD subphenotypes. Color intensity corresponds to the strength of the enrichment signal, with subphenotypes ordered by effect size. Absence of color indicates no association. Asterisks (*) denote associations that remained robust after Bonferroni correction for the number of cell types tested ($P < .05$). Corresponding results from the BD-only analysis are shown in eFigure 12. The eTable 12 provides the full list of gene-tissue associations from the TWAS analysis.

Figure 4. Gene-Set Enrichment Results from the bipolar disorder-schizophrenia (BD-SCZ) Analysis. The heatmap displays standardized beta coefficients from MAGMA gene-set enrichment analysis across 10 BD subphenotypes. Color intensity corresponds to the strength of the enrichment signal, with gene sets ordered by effect size. Absence of color indicates no association. Asterisks (*) denote associations that remained robust after Bonferroni correction for the number of gene sets tested (*P* < .05). Corresponding results from the BD-only analysis are shown in eFigure 13. The eTable 14 provides the full list of gene-set associations.

Table 1. Key Genetic and Biological Findings Defining the Dimensions of Bipolar Disorder

Pathway	Key Finding	Primary Evidence	Analysis
Severe Illness Dimension (Psychosis, SZA)			
Neuro-Immune	*HLA-DMB*	Protective; $P = 2.50 \times 10^{-273}$	TWAS (BD-SCZ MTAG)
Synaptic Function	*SCN2A*	Deleterious; CADD = 19.83	Variant Annotation
Synaptic Function	Postsynaptic Specialization	P (Bonferroni) $< 1.35 \times 10^{-12}$	Gene-Set Enrichment
Cellular	VIP-expressing interneurons	Top enriched cell type	Cell-Type Enrichment
Neurodevelopment	Hippocampal Excitatory Neurons (exDG)	Enrichment in BD-SCZ analysis	Cell-Type Enrichment
Core Mania Dimension (BD1)			
Synaptic Function	*PACS1*	$P = 2.00 \times 10^{-19}$	TWAS (BD-only)
Externalizing Dimension (SA, AlcSUD)			
Cellular	Midbrain Dopaminergic Neurons	Risk enrichment	Cell-Type Enrichment
Neurodevelopment	*MAD1L1*	Novel Locus; $P = 1.15 \times 10^{-15}$	GWAS (BD-SCZ MTAG)
Internalizing Dimension			
Neurodevelopment	*DCC* (RC, UM, PD, OCD)	Shared Locus; $P < 1.37 \times 10^{-6}$	LAVA
Neuro-Immune	*SMAD3* (RC, PD)	PD/RC Specific Locus; $P = 3.14 \times 10^{-8}$	GWAS (BD-SCZ MTAG)
Cellular (Gut-Brain)	*GLP2R* enrichment (PD)	Specific cell-type enrichment	Cell-Type Enrichment
Cellular	Glutamatergic vs. GABAergic signaling (BD2)	Weaker glutamatergic assoc.	Cell-Type Enrichment
Evolutionary	Rapid Cycling (RC)	Negative Selection (S) = -1.75	SBayesS
Shared / Foundational (Across Dimensions)			
Foundational	Chromatin Org. & DNA Repair	Top enriched pathway	Gene-Set Enrichment
Systemic (Stress)	Nicotine/Chromaffin Cell Pathway	Enriched in BD-SCZ analysis	Gene-Set Enrichment
Systemic (Metabolic)	*SLC39A8, FADS1*	CADD=23.1; $P = 2.11 \times 10^{-32}$	Variant Annotation, TWAS
Synaptic (Endocannabinoid)	*CNR1* enrichment	Shared vulnerability	Cell-Type Enrichment
Synaptic (Metabolic)	*GLYCTK*	Protective; $P = 5.20 \times 10^{-110}$	TWAS (Amygdala)

Abbreviations: AlcSUD, alcohol/substance use disorder; BD1, bipolar disorder I; BD2, bipolar disorder II; CADD, Combined Annotation Dependent Depletion; GWAS, Genome-Wide Association Study; LAVA, Local Analysis of [co]Variant Annotation; MTAG, Multi-Trait Analysis of GWAS; OCD, obsessive-compulsive disorder; PD, panic disorder; RC, rapid cycling; SA, suicide attempt; SZA, schizoaffective disorder, bipolar type; TWAS, Transcriptome-Wide Association Study; UM, unipolar mania.